Alpha 2.0
Login Register
» Articles » PMID: 19624312

Targeting Mutant BRAF and KIT in Metastatic Melanoma: ASCO 2009 Meeting Report

Overview
Journal Pigment Cell Melanoma Res
Date 2009 Jul 24
PMID 19624312
Citations 5
Authors
Vernon K Sondak
Keiran Smalley
Affiliations
Soon will be listed here.
Citing Articles

Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.

Pandey M, Gowda K, Doi K, Sharma A, Wang H, Amin S PLoS One. 2013; 8(11):e78570.

PMID: 24223823 PMC: 3817219. DOI: 10.1371/journal.pone.0078570.

Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry.

Beadling C, Heinrich M, Warrick A, Forbes E, Nelson D, Justusson E J Mol Diagn. 2011; 13(5):504-13.

PMID: 21726664 PMC: 3157616. DOI: 10.1016/j.jmoldx.2011.04.003.

Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells.

Kaplan F, Shao Y, Mayberry M, Aplin A Oncogene. 2010; 30(3):366-71.

PMID: 20818433 PMC: 6591715. DOI: 10.1038/onc.2010.408.

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Tap W, Gong K, Dering J, Tseng Y, Ginther C, Pauletti G Neoplasia. 2010; 12(8):637-49.

PMID: 20689758 PMC: 2915408. DOI: 10.1593/neo.10414.

Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells.

Shao Y, Aplin A Cancer Res. 2010; 70(16):6670-81.

PMID: 20647317 PMC: 2922482. DOI: 10.1158/0008-5472.CAN-09-4471.